KALV

KalVista Pharmaceuticals, Inc. (KALV) Economic Moat Analysis (2026)

Invetso Score: 2.4/10 — Weak · Last Updated: 2026-08-01

Overall Score

Profitability Returns

Gross margin remains very high at 92.0%, but operating margin is deeply negative at -120.8% and net margin at -119.4%.

Returns remain severely negative, with ROA at -41.3%, ROE at -1057.4%, and ROIC at -46.8%.

Balance Sheet Liquidity

Liquidity is strong with a current ratio of 5.58x and quick ratio of 5.52x.

Cash per share of $5.94 exceeds debt per share of $6.07, but leverage remains elevated with debt-to-assets at 84.7%.

Efficiency Cash Conversion

Asset turnover is modest at 0.35x despite strong fixed-asset turnover of 9.01x.

Cash conversion is favorable with a negative cash conversion cycle of -155.5 days, but operating cash flow remains negative at -$1.11 per share.

Valuation Market Expectations

Valuation remains rich at 12.9x EV/Sales and 12.4x P/S despite negative earnings and cash flow.

Free cash flow yield is negative at -3.9%, indicating the market is pricing in substantial future improvement.

Moat Indicators

Gross margin strength suggests some pricing power or product differentiation, but it is not translating into durable operating profits.

No clear evidence of a durable economic moat is visible in the current financial profile, given persistent losses and weak returns on capital.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on KalVista Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →